These commercially supported Product Theaters are independent of the American Academy of Otolaryngic Allergy (AAOA) educational activities and are not accredited by AAOA.

2023 AAOA Basic Course in Allergy & Immunology

Sanofi and Regeneron

Take a Different Path to Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) Control
Presenter: David Yen, MD

Friday June 30th 12:15PM-1:15PM PDT
Location: Hyatt Regency, Seattle, WA @ Quinault

2023 AAOA Annual meeting

Friday, September 29

12:15-1:15 PM CT

GSK

The Expected and Unexpected Roles of Key Inflammatory Mediators in CRSwNP and Associated Systemic Diseases

Speakers:

Katie Buchheit, MD

• Associate Program Director, Allergy/Immunology Fellowship
• Assistant Professor of Medicine, Harvard Medical School
• Brigham and Women’s Hospital, Boston, Massachusetts

Justin Turner, MD, PhD

• Associate Professor, Department of Otolaryngology–Head and Neck Surgery
• Vice Chair for Research, Vanderbilt University School of Medicine

Discription/Objectives

An interactive, disease state program on chronic rhinosinusitis with nasal polyposis (CRSwNP). This multidisciplinary panel discussion will focus on the expected and unexpected roles of key inflammatory mediators in CRSwNP, alongside other systemic diseases featuring CRSwNP, that sets the pathophysiologic foundational understanding of diseases and optimization of care in daily practice.

Location: Embassy Suites by Hilton Nashville Downtown, Riverbed C

____________________________________________________________________________________________________________________________________________

Saturday, September 30

8:00 – 9:00 AM CT

GSK

What’s Driving Recurrent Disease in Your Patients? Targeting Eosinophils with NUCALA as an Option for Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Speakers:  Christine Franzese, MD, FAAOA, FAR; Professor, Department of Otolaryngology and Director of Allergy at the University of Missouri and Christopher Melroy, MD, FAR; Georgia Nasal and Sinus Institute, and Clinical Assistant Professor, Department of Surgery, Mercer University School of Medicine

Main Objectives: Discuss the clinical features of patients struggling with CRSwNP; review the role of eosinophils as a driver of severe, recurrent CRSwNP, and discuss potential approaches to identifying patients who may benefit from NUCALA, a targeted biologic treatment.  Clinical trial evidence for the use of NUCALA as a non-surgical treatment option will be discussed.  An open period for Q&A will be included.

Location: Embassy Suites by Hilton Nashville Downtown, Riverbed C

___________________________________________________________________________________________________________________________________________

Saturday, September 30

11:50 AM – 12:50 PM CT

Sanofi and Regeneron

Inhibiting IL-4 and IL-13 Signaling Across CRSwNP and EoE

Speaker:

Dareen Siri, MD, Assistant Professor, Dept of Otolaryngology Head & Neck Surgery, Southern IL Univ School of Medicine Allergist/Immunologist, Chief Executive Officer, and Medical Director Midwest Allergy, Sinus, Asthma, SC
Normal, IL

Location: Embassy Suites by Hilton Nashville Downtown, Riverbed C

__________________________________________________________________________________________________________________________________________

Sunday, October 1

8:00 – 9:00 AM CT

Integrity Continuing Education, Inc.

Severity Assessment, Patient Selection, and Comparison of Treatment Options for CRSwNP: Are We Ready to Set our Sights on a Standard?

Speakers:

Anju T. Peters, MD
Professor of Medicine
Director of Clinical Research
Division of Allergy/Immunology and Otolaryngology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Stella Lee, MD
Section Chief Rhinology
Brigham and Women’s Hospital
Harvard Medical School
Weston, Massachusetts

Michael Platt, MD, MSc
Associate Professor and Residency Director
Director of Rhinology and Endoscopic Skull Base Surgery
Department of Otolaryngology- Head and Neck Surgery
Chobanian and Avedesian School of Medicine
Boston University
Boston, Massachusetts

Learning objectives:

• Apply evidence-based guidance to assess the severity and QOL impact of CRSwNP
• Evaluate clinical trial data on the efficacy and safety of biologics and surgical options for patients with CRSwNP
• Incorporate current guidelines and expert recommendations into the positioning of biologic therapy, sinus surgery, and OCS for the treatment of patients with CRSwNP

Location: Embassy Suites by Hilton Nashville Downtown, Riverbed C and Whova app

These commercially supported Product Theaters are independent of the American Academy of Otolaryngic Allergy (AAOA) educational activities and are not accredited by AAOA.